Compare GSK plc (GSK) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Wix.Com Ltd — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Wix.Com Ltd trades at $76.56 (market cap $3.11B). The key difference: GSK plc is far larger — about 29.5× Wix.Com Ltd's market cap, and GSK plc pays a 3.9% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Wix.Com Ltd for 62 Days on average.
| GSK | WIX | |
|---|---|---|
Market Cap | $91.88B | $3.11B |
Volume | 7,730,529 | 809,286 |
Sector | Health | Technology |
52-Week High | $61.18 | $145.54 |
52-Week Low | $43.24 | $40.43 |
Typical Hold Time | 93 Days | 62 Days |
Enterprise Value | $111.88B | $4.19B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Wix.com (WIX) trades at $76.56, up 4.92% in the last 24 hours, with technical indicators showing a neutral to bullish bias. Revenue growth is robust, reaching $1.99B in 2025, but profitability is inconsistent, with a net income margin of -8.19% in 2026. Analyst sentiment is positive, with a consensus buy rating and a $77 price target, though recent class action lawsuits add caution.
The outlook for WIX hinges on sustaining revenue growth while improving profitability. Risks include legal challenges and volatile earnings, but strong analyst support and a solid market position offer potential upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
